Biosimilars: An uncertain path to promise: As the costs of drugs rise - Will biosimilars fulfill their promise of affordability?

Pharmaceutical Processing

Volumn 27, Issue 9, 2012, Pages 36-39

  Howell, Peyton ^a   Burich, Molly ^a  

^a AmerisourceBergen Consulting Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BEVACIZUMAB; BIOSIMILAR AGENT; ETANERCEPT; INFLIXIMAB; INSULIN GLARGINE; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; TRASTUZUMAB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; DRUG COST; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; INVESTMENT; UNITED STATES; COST; FOOD AND DRUG ADMINISTRATION; PATENT;

EID: 84867252643     PISSN: 10499156     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (6)

1. IMS white paper. Shaping the Biosimilars Opportunity: A Global Perspective on the Evolving Biosimilars Landscape. November 2011.
2. Patient Protection and Affordable Care Act Full Text Sections 7001-7002. http://housedocs.house.gov/energycommerce/ppacacon.pdf. Accessed May 30, 2012.
3. Generic Pharmaceutical Association website. About Generics.http://www.gphaonline.org/about-gpha/about-generics. Accessed June 5, 2012.
4. Government Accountability Office Report. Research on Savings from Generic Drug Use.http://www.gao.gov/products/GAO-12-371R. Accessed June 4, 2012.
5. Evaluate Pharma website. Biotech Set to Dominate Drug Industry Growth. http://www.evaluatepharma.com/Universal/View.aspx?type=Story&id=188700§ionID=&isEPVantage=yes. Accessed June 6, 2012.
6. Evaluate Pharma website. Biotech Set to Dominate Drug Industry Growth. http://www.evaluatepharma.com/Universal/View.aspx?type=Story&id=188700§ionID=&isEPVantage=yes. Accessed June 6, 2012.